Skip to content
value.today
MedMen logo

MedMen

MMNWF
No market cap data
Compare
World rank
—
no current market cap
Revenue
$141 M
For year ending June-2022
Net income
$211 M
149.8% margin
SEC filing
Employees
—

MedMen in brief

MedMen is a listed company, based in Los Angeles, USA. In the year to June 2022 it had sales of $141 M and a net profit of $211 M. Its shares trade under the symbol MMNWF (OTC Markets Group).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About MedMen

MedMen Enterprises was a United States-based cannabis company. At its peak, it had operations in California, Nevada, Arizona, Florida, Illinois, New York, and Massachusetts. MedMen owns and operates 29 retail stores and 6 cultivation facilities and is currently licensed to expand its footprint to 65 retail locations. Its stock began trading on the Canadian Securities Exchange under the ticker symbol MMEN in 2018. The CSE suspended trading of MedMen's stocks on January 8, 2024 pursuant to cease trade orders from the Ontario Securities Commission and British Columbia Securities Commission, and the stocks were delisted on May 16, 2024. MedMen was also traded over-the-counter in the United States under the ticker symbol MMNFF. MedMen is based in Culver City, California and has more than 1,000 employees.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

MedMen timeline

1 events, 2019
  1. 2019
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.

Events of MedMen from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
—
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
149.8%
Operating margin
-120.0%
Return on equity
131.9%
Liabilities / assets
198.3%
Revenue growth
+6.5%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Jun 2020: revenue $155M, net income $527M$155MFY20Fiscal year ending Jun 2021: revenue $132M, net income $158M$132MFY21Fiscal year ending Jun 2022: revenue $141M, net income $211M$141MFY22
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Jun 2022$141M+6.5%$-169M$211M149.8%
Jun 2021$132M-14.8%$-55M$158M119.2%
Jun 2020$155M—$-432M$527M339.1%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Jun 2022$-63M$9M$-72M——
Jun 2021$-59M$3M$-62M——
Jun 2020$-110M$57M$-167M——

SEC filings

Official filings of MedMen with the US Securities and Exchange Commission.

Annual results

Revenue
$141 M
Operating income
$-169 M
Net income
$211 M

For year ending June-2022 · source: SEC filing

Balance sheet

Total assets
$321 M
Total liabilities
$636 M
Total equity
$160 M

As of June-2022

Insider trading at MedMen#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
20
since
MedMen: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Melony ValleauCAOGrant or award+5.10 M——5.10 MForm 4
filed Amit PandeyCFOGrant or award+13.16 M$0.020$263 K13.16 MForm 4
filed Cameron Dovi SmithDirectorGrant or award+143,449——984,022Form 4
filed Edward J. RecordDirectorGrant or award+143,449——158,373Form 4
filed Errol SchweizerDirectorGrant or award+106,028——1.23 MForm 4
filed Melvin EliasDirectorGrant or award+160,775——1.04 MForm 4
filed David HsuDirectorGrant or award+143,449——158,373Form 4
filed David HsuDirectorGrant or award+14,924——14,924Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

MedMen scorecard#

Passes 3 of the 5 checks that could be worked out. Fiscal year 2021.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth1 of 1
    • ✓Revenue grew in the newest year6.5%Revenue up 6.5% in fiscal 2021.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability2 of 2
    • ✓Profitable in the newest year$211 MNet income $211 M in fiscal 2021.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianToo few peers for a median.
    • ✓Return on equity above 15%119.9%119.9% in fiscal 2021.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 2
    • ✗Short-term assets cover short-term liabilities0.5×Current ratio 0.51 at the end of fiscal 2021.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2021.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

MedMen: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

MedMen: statements by fiscal year
PeriodTrendFY 2021to Jun 25, 2022FY 2020to Jun 26, 2021FY 2019to Jun 27, 2020
Income statement
Revenue141132r155
Cost of revenue7172r100
Gross profit7061r55
Selling and marketing3.21.0r11
General and administrative109109r193
Operating expenses239116r488
Operating income−169−55r−432
Net interest income3231r34
Other non-operating income (expense)6.567r65
Income before tax−166−124r−457
Income tax−9.91.8−41
Income from continuing operations−166−124r−457
Income from discontinued operations−45−12−22
Net income attributable to shareholders211158527
Shares, weighted average (basic)—531270
Shares, weighted average (diluted)—531270
Balance sheet
Cash and cash equivalents11r12r9.6r
Inventory1016r21r
Other current assets8.9r7.9r9.2r
Current assets160r176r73r
Property, plant and equipment64107r166r
Right-of-use (leased) assets43r62r100r
Goodwill9.8r33r33r
Other intangible assets41r83r140r
Total assets321r472r574r
Accounts payable33r45r77r
Current liabilities314r347r183r
Lease liabilities (non-current)51r62r116r
Total liabilities636r726r751r
Retained earnings−897r−717r−631r
Shareholders' equity160r192r160r
Minority interests−475r−445r−337
Total equity−315r−254r−177r
Total liabilities and equity321r472r574r
Cash-flow statement
Depreciation and amortization2628r41
Share-based compensation5.35.511
Cash from operating activities−63−59r−110
Capital expenditure−9.0−2.7r−57
Intangible assets bought−0.6−1.2r−4.1
Acquisitions, net of cash acquired——−0.6
Cash from investing activities−1111r−19
Cash from financing activities7351107
Report10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Mar 25, 2023. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at MedMen#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Financial statements withdrawn 1 · Auditor changed 1 · Debt called early 1 · Acquisition or sale completed 2 · Directors and officers 16 · Material agreement 4 · Agreement ended 1 · New debt 2 · Unregistered share sale 2 · Shareholder vote 2 · Results announced 3

MedMen: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Directors and officers8-K
Acquisition or sale completed8-K
Material agreement8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Financial statements withdrawn8-K
Auditor changed8-K
Acquisition or sale completed8-K
Directors and officersShareholder vote8-K
Directors and officers8-K
Shareholder vote8-K
Material agreement8-K
Directors and officers8-K
Directors and officers8-K
Debt called earlyDirectors and officersMaterial agreementNew debtUnregistered share sale8-K
Directors and officersAgreement ended8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Directors and officersMaterial agreementNew debtUnregistered share sale8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Jan 30, 2024

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of MedMen
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2019$17 MNo. 3$10 to $50 million5equitySEC
Aug 2019$30 MNo. 2$10 to $50 million1equitySEC
Apr 2019$125 MNo. 1$50 to $250 million1debt, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Questions, comparisons and similar companies#

Sources and freshness

Annual results:
For year ending June-2022
Balance sheet:
As of June-2022
Profile updated:
Nov 16, 2026

Figures from SEC filing, Wikidata, Wikipedia, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at MedMen? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show MedMen's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about MedMen? Suggest a correction